Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 11, 2015, Pages E1317-E1325

  Jiang, Peiyong ^a,b   Chan, Carol W M ^a,b   Chan, K C Allen ^a,b   Cheng, Suk Hang ^a,b   Wong, John ^b   Wong, Vincent Wai Sun ^a,b   Wong, Grace L H ^a,b   Chan, Stephen L ^a,b   Mok, Tony S K ^a,b   Chan, Henry L Y ^a,b   Lai, Paul B S ^a,b   Chiu, Rossa W K ^a,b   Lo, Y M Dennis ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Circulating tumor DNA; Liquid biopsy; Massively parallel sequencing; Mitochondrial DNA; Tumor markers

Indexed keywords

CELL NUCLEUS DNA; DNA FRAGMENT; MITOCHONDRIAL DNA; PLASMA DNA; UNCLASSIFIED DRUG; DNA;

ARTICLE; CANCER DIAGNOSIS; CHROMOSOME ABERRATION; CHROMOSOME ARM; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA EXTRACTION; DNA SEQUENCE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; BASE PAIRING; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENETICS; HUMAN CHROMOSOME; LIVER TUMOR; MOLECULAR WEIGHT; RECEIVER OPERATING CHARACTERISTIC;

BASE PAIRING; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; DNA, NEOPLASM; HEPATITIS B; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MOLECULAR WEIGHT; ROC CURVE;

EID: 84925338452     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500076112     Document Type: Article

References (51)

1. Jung K, Fleischhacker M, Rabien A (2010) Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin Chim Acta 411(21-22):1611-1624.
2. Chan KCA (2013) Scanning for cancer genomic changes in plasma: Toward an era of personalized blood-based tumor markers. Clin Chem 59(11):1553-1555.
3. Bidard FC, Weigelt B, Reis-Filho JS (2013) Going with the flow: From circulating tumor cells to DNA. Sci Transl Med 5(207):07ps14.
4. Beck J, Urnovitz HB, Mitchell WM, Schütz E (2010) Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 8(3):335-342.
5. Dawson SJ, et al. (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368(13):1199-1209.
6. Chan KCA, et al. (2013) Cancer genome scanning in plasma: Detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59(1):211-224.
7. Heitzer E, et al. (2013) Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 133(2):346-356.
8. Heitzer E, et al. (2013) Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5(4):30.
9. Leary RJ, et al. (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4(162):ra154.
10. Chan KCA, et al. (2013) Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA 110(47):18761-18768.
11. Chan KCA, et al. (2008) Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 54(9):1528-1536.
12. Wong IH, et al. (1999) Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59(1):71-73.
13. Balgkouranidou I, et al. (2014) Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br J Cancer 110(8):2054-2062.
14. Diehl F, et al. (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102(45):16368-16373.
15. Yung TKF, et al. (2009) Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15(6):2076-2084.
16. Murtaza M, et al. (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447):108-112.
17. Forshew T, et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4(136):36ra68.
18. Lo YMD, et al. (1999) Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59(6):1188-1191.
19. Chan KCA, et al. (2013) Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 119(10):1838-1844.
20. McBride DJ, et al. (2010) Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49(11):1062-1069.
21. Leary RJ, et al. (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2(20):20ra14.
22. Chan KCA, Leung SF, Yeung SW, Chan ATC, Lo YMD (2008) Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res 14(13):4141-4145.
23. Gao YJ, et al. (2010) Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med 48(11):1651-1656.
24. Umetani N, et al. (2006) Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats. Clin Chem 52(6):1062-1069.
25. Wang BG, et al. (2003) Increased plasma DNA integrity in cancer patients. Cancer Res 63(14):3966-3968.
26. Umetani N, et al. (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24(26):4270-4276.
27. Mouliere F, et al. (2011) High fragmentation characterizes tumour-derived circulating DNA. PLoS One 6(9):e23418.
28. Lo YMD, et al. (2010) Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2(61):61ra91.
29. Zheng YWL, et al. (2012) Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: A transplantation model. Clin Chem 58(3):549-558.
30. Yu SCY, et al. (2014) Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proc Natl Acad Sci USA 111(23):8583-8588.
31. Pleasance ED, et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278):191-196.
32. Fujimoto A, et al. (2012) Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44(7):760-764.
33. Tao Y, et al. (2011) Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci USA 108(29):12042-12047.
34. Totoki Y, et al. (2011) High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43(5):464-469.
35. Beroukhim R, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463(7283):899-905.
36. Chiang DY, et al. (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68(16):6779-6788.
37. Kan Z, et al. (2013) Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 23(9):1422-1433.
38. Kim TM, et al. (2008) Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 123(12):2808-2815.
39. Lo YMD, et al. (1998) Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet 62(4):768-775.
40. Mouliere F, et al. (2013) Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol 6(3):319-328.
41. Chan KCA, et al. (2003) Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63(9):2028-2032.
42. Nakano H, Shinohara K (1994) X-ray-induced cell death: Apoptosis and necrosis. Radiat Res 140(1):1-9.
43. Walker NI, Harmon BV, Gobé GC, Kerr JF (1988) Patterns of cell death. Methods Achiev Exp Pathol 13:18-54.
44. van der Vaart M, Semenov DV, Kuligina EV, Richter VA, Pretorius PJ (2009) Characterisation of circulating DNA by parallel tagged sequencing on the 454 platform. Clin Chim Acta 409(1-2):21-27.
45. Alexandrov LB, et al.; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415-421.
46. Kelly RD, Mahmud A, McKenzie M, Trounce IA, St John JC (2012) Mitochondrial DNA copy number is regulated in a tissue specific manner by DNA methylation of the nuclear-encoded DNA polymerase gamma A. Nucleic Acids Res 40(20):10124-10138.
47. Mengel-From J, et al. (2014) Mitochondrial DNA copy number in peripheral blood cells declines with age and is associated with general health among elderly. Hum Genet 133(9):1149-1159.
48. Lui YYN, et al. (2002) Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 48(3):421-427.
49. Li R, et al. (2009) SOAP2: An improved ultrafast tool for short read alignment. Bioinformatics 25(15):1966-1967.
50. Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9(4):357-359.
51. Chen EZ, et al. (2011) Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One 6(7):e21791.